Product Details
ACTEMRA 400MG/20ML SDV EA
Manufacturer: GENENTECH, INC
MFG#: 50242-0137-01
NDC: 50242-0137-01
PID: 639031
1/EA
$ *.**
In StockAdditional Information
| Product Name | Actemra 400 mg/20 mL Single-Dose Vial |
| Active Ingredient | Tocilizumab |
| Mechanism of Action | IL-6 receptor antagonist, reducing inflammation |
| Therapeutic Class | Monoclonal Antibody |
| Concentration | 400 mg/20 mL (20 mg/mL) |
| Administration Route | IV infusion or subcutaneous injection |
| Preparation | Requires dilution for IV infusion |
| Common Adverse Effects | Infections, infusion reactions, elevated liver enzymes, neutropenia, gastrointestinal symptoms |
| Serious Adverse Effects | Severe infections, hepatotoxicity, gastrointestinal perforation, demyelinating disorders |
| Monitoring Parameters | Liver function, neutrophil count, lipid profile |
| Storage Conditions | 2°C to 8°C (36°F to 46°F), protect from light, do not freeze or shake |
| Packaging | Single dose vial |
| Indications | Rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis |
Description
Actemra 400 mg/20 mL Single-Dose Vial contains tocilizumab, a recombinant humanized monoclonal antibody that specifically targets the interleukin-6 (IL-6) receptor. By inhibiting IL-6 signaling, it reduces inflammation and immune system overactivity. It is indicated for the treatment of rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, and cytokine release syndrome.
The formulation is supplied as a sterile, preservative-free solution in a single-dose vial for intravenous (IV) infusion or subcutaneous injection, depending on the condition being treated. Administration should be performed under medical supervision due to the risk of serious hypersensitivity reactions.
Common adverse effects include infections, infusion-related reactions, elevated liver enzymes, neutropenia, and gastrointestinal symptoms. Serious risks include severe infections, gastrointestinal perforation, hepatotoxicity, and demyelinating disorders. Routine monitoring of liver function, neutrophil counts, and lipid profiles is required to minimize complications.
Frequently Asked Questions (FAQs)
The cost of ACTEMRA 400MG/20ML SDV EA is $$0.00
ACTEMRA 400MG/20ML SDV EA is manufactured by GENENTECH, INC.
You can purchase ACTEMRA 400MG/20ML SDV EA on our website at https://supplies.pipelinemedical.com/product/detail/actemra-400mg-20ml-sdv-ea-648343